Inossia

Inossia is a startup based in Sweden. Brouky classifies it under Healthcare & Life Sciences.

Inossia develops a softening additive for bone cements used in vertebral augmentation to better match the mechanical properties of osteoporotic bone, aiming to reduce the risk of new spinal fractures. The company is conducting a large randomized multicenter clinical trial across hospitals in multiple countries and has received US FDA Breakthrough Device designation.